FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Miguel Martín

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Circulating Neoplastic Cells

Geographic Areas

Spain

Co-author Network

Publications

TOP 3
A Romero; Miguel de la Hoya; J de la Torre; E Diaz-Rubio; V Furio; J A García-Sáenz; Miguel Martín; A Moreno; B Oliva; J M Román; Trinidad Caldés
Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients.
Sara López-Tarruella; Iván Márquez-Rodas; Yolanda Jerez; Miguel Martín
Neratinib (HKI-272) in the treatment of breast cancer.
Atocha Romero; Trinidad Caldés; Eduardo Díaz-Rubio; Miguel Martín
Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Miguel Martín (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: A Romero; Miguel de la Hoya; J de la Torre; E Diaz-Rubio; V Furio; J A García-Sáenz; Miguel Martín; A Moreno; B Oliva; J M Román; Trinidad Caldés
Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(7):1750-6.
2012: Sara López-Tarruella; Iván Márquez-Rodas; Yolanda Jerez; Miguel Martín
Neratinib (HKI-272) in the treatment of breast cancer.
Future oncology (London, England) 2012;8(6):671-81.
2012: Atocha Romero; Trinidad Caldés; Eduardo Díaz-Rubio; Miguel Martín
Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2012;14(3):163-8.
2012: Joan Albanell; B Bermejo; O Burgues; ramon colomer; J M Corominas; I Faull; V Furio; J A García-Saenz; A González; M L Limon; Miguel Martín; M Martínez-García; A S Muñoz; J Palacios; A Rojo; F Rojo; Manuel Ruiz Borrego; Ignasi Tusquets; Emilio Alba; Ana Lluch
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(3):625-31.
2012: José A Serra-Rexach; Maite Vidán; Javier Ortiz; Rosa Pla; Paz Rodríguez; P García Alfonso; María A García-Alhambra; Ana B Jimenez; Miguel Martín
Differences in the therapeutic approach to colorectal cancer in young and elderly patients.
The oncologist 2012;17(10):1277-85.
2012: Iván Márquez-Rodas; Felipe A Calvo; Sara Custodio Cabello; Daniel López-Trabada; María Orera Clemente; María Isabel Peligros Gómez; Ana Belén Rupérez Blanco; Miguel Martín
Family history record and hereditary cancer risk perception according to National Cancer Institute criteria in a Spanish medical oncology service: a retrospective study.
Oncology 2012;82(1):30-4.
2011: Atocha Romero; Miguel Martín; Maggie C U Cheang; José Antonio López García-Asenjo; Belén Oliva; Xiaping He; Miguel de la Hoya; Jose Ángel García Sáenz; Manuel Arroyo Fernández; Eduardo Díaz-Rubio; Charles M Perou; Trinidad Caldés Llopis
Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
The American journal of pathology 2011;178(4):1453-60.
2011: José A García-Sáenz; Ana Custodio; Antonio Casado; José Antonio Vidart; Pluvio J Coronado; Miguel Martín; Sara López-Tarruella; Javier Puente; Cristina Fernández; Eduardo Díaz-Rubio
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2011;13(2):121-32.
2011: Juan de la Haba Rodríguez; Alvaro Rodríguez-Lescure; Amparo Ruiz; Emilio Alba; Lourdes Calvo; Eva Carrasco; Maria Jose Escudero; Miguel Martín
Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer.
Breast cancer research and treatment 2011;125(1):273-8.
2010: José M Jerez; Ignacio Molina; Pedro J García-Laencina; Emilio Alba; Nuria Ribelles; Miguel Martín; Leonardo Franco
Missing data imputation using statistical and machine learning methods in a real breast cancer problem.
Artificial intelligence in medicine 2010;50(2):105-15.
2010: Miguel Martín; Alvaro Rodríguez-Lescure; Amparo Ruiz; Emilio Alba; Lourdes Calvo; Manuel Ruiz Borrego; Ana Santaballa; César A Rodríguez; Carmen Crespo; Mar Abad; Severina Domínguez; Jesús Florián; Cristina Llorca; Miguel Méndez; María Godes; Ricardo Cubedo; Adolfo Murias; Norberto Batista; María José García; Rosalía Caballero; Enrique de Alava
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer.
Breast cancer research and treatment 2010;123(1):149-57.
2010: Emilio Alba; Manuel Ruiz Borrego; Mireia Margelí; Alvaro Rodríguez-Lescure; Pedro Sánchez-Rovira; Amparo Ruiz; Jose Ramón Mel-Lorenzo; Manuel Ramos-Vázquez; Nuria Ribelles; Elisa Calvo; Antonio Casado; Antonia Márquez; David Vicente; José Angel García-Sáenz; Miguel Martín
Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.
Breast cancer research and treatment 2010;122(1):169-76.
2010: Ignasi Tusquets; L García-Estévez; Encarna Adrover; L Calvo; Isabel Alvarez; Jesús García-Mata; Y Fernández; M Margueli; Miguel Angel Seguí; M Muñoz; C Rodríguez; Alvaro Rodríguez-Lescure; ramon colomer; P Gascón; Miguel Martín; Emilio Alba; A Barnadas; A Llombart; Joan Albanell; Ana Lluch
Current controversies in the management of breast cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2010;12(4):278-86.
2009: Luisa M Maestro; Javier Sastre; Sara B Rafael; Silvia B Veganzones; Marta Vidaurreta; Miguel Martín; Carlos Olivier; Virginia B DE La Orden; Jose Angel Garcia-Saenz; Rosario Alfonso; Manuel Arroyo; Eduardo Diaz-Rubio
Circulating tumor cells in solid tumor in metastatic and localized stages.
Anticancer research 2009;29(11):4839-43.
2009: Miguel Martín; José A García-Sáenz; Maria Luisa Maestro De las Casas; Marta Vidaurreta; Javier Puente; Silvia Veganzones; Laura Rodríguez-Lajusticia; Virginia De la Orden; Belén Oliva; Julio-César De la Torre; Sara López-Tarruella; Antonio Casado; Javier Sastre; Eduardo Díaz-Rubio
Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis.
Anticancer research 2009;29(10):4185-7.
2009: José A García-Sáenz; Miguel Martín; María Luisa Maestro; Marta Vidaurreta; Silvia Veganzones; Sara Rafael; Antonio Casado; Jana Bobokova; Javier Sastre; Virginia De la Orden; Manuel Arroyo; Eduardo Díaz-Rubio
Circulating tumour cells in locally advanced breast cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2009;11(8):544-7.
2009: Sara López-Tarruella; Miguel Martín
Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.
Breast cancer research : BCR 2009;11(2):204.
2009: Miguel Martín; Francisco J Esteva; Emilio Alba; Bijoy Khandheria; Leopoldo Pérez-Isla; José A García-Sáenz; Antonia Márquez; Partho Sengupta; José Zamorano
Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
The oncologist 2009;14(1):1-11.
2008: Juan de la Haba Rodríguez; Emilio Alba; Agustí Barnadas; Eloisa Bayo; Antonio Llombart; Ana Lluch; Miguel Martín; José Andrés Moreno-Nogueira; Gumersindo Pérez Manga; Alvaro Rodríguez-Lescure; Enrique Aranda
Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2008;10(9):552-9.
2008: Juan de la Haba Rodríguez; Enrique Aranda; Antonio Llombart; Ana Lluch; Emilio Alba; Blanca Munárriz; Encarna Adrover; Ignacio Tusquets; Ana Balil; Agustí Barnadas; Lourdes Calvo; Miguel Martín
Time-to-progression in breast cancer: a stratification model for clinical trials.
Breast (Edinburgh, Scotland) 2008;17(3):239-44.
2008: Javier Sastre; María Luisa Maestro; J Puente; Silvia Veganzones; R Alfonso; Sara Rafael; J A García-Saenz; Marta Vidaurreta; Miguel Martín; M Arroyo; María Teresa Sanz-Casla; Eduardo Díaz-Rubio
Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(5):935-8.
2007: Laura G Estévez; Miguel Martín; Emilio Alba; ramon colomer; Francisco Lobo; Ana Lluch; Encarna Adrover; Joan Albanell; Agustí Barnadas; Jesús García-Mata; Antonio Llombart; Monserrat Muñoz; C Rodríguez; Pedro Sánchez-Rovira; Miguel Angel Seguí; Ignasi Tusquets
Current controversies in the management of early breast cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007;9(6):375-84.
2007: Carmen Cañadas; Ana Sánchez de Abajo; Juan Manuel Fernández; Miguel Martín; Eduardo Diaz-Rubio; Trinidad Caldés; Miguel de la Hoya
Molecular haplotyping of tandem single nucleotide polymorphisms by allele-specific PCR.
Analytical biochemistry 2007;364(2):153-8.
2007: C Bueno Muiño; Javier Puente Vázquez; Javier Sastre Valera; José A García-Sáenz; Miguel Martín; N García Miralles; Andrés Sánchez-Pernaute; Eduardo Díaz-Rubio
Pathological complete response following docetaxel-based neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007;9(5):335-8.
2007: Miguel Martín; Amparo Ruiz; Monserrat Muñoz; Anna Balil; Jesús García-Mata; Lourdes Calvo; Eva Carrasco; Esther Mahillo; Antonio Casado; José Angel García-Saenz; M José Escudero; Vicente Guillem; Carlos Jara; Nuria Ribelles; Fernando Salas; Celia Soto; Flavia Morales-Vasquez; César A Rodríguez; Encarna Adrover; José Ramón Mel
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
The lancet oncology 2007;8(3):219-25.
2007: Carlos Jara-Sánchez; Amparo Ruiz; Miguel Martín; Antonio Antón; Blanca Munárriz; Arrate Plazaola; José Schneider; Purificación Martínez del Prado; Emilio Alba; Antonio Fernández-Aramburo
Influence of timing of initiation of adjuvant chemotherapy over survival in breast cancer: a negative outcome study by the Spanish Breast Cancer Research Group (GEICAM).
Breast cancer research and treatment 2007;101(2):215-23.
2006: José A García-Sáenz; Miguel Martín; María Luisa Maestro; Marta Vidaurreta; Silvia Veganzones; Laura Villalobos; Laura Rodríguez-Lajusticia; Sara Rafael; María Teresa Sanz-Casla; Antonio Casado; Javier Sastre; Manuel Arroyo; Eduardo Díaz-Rubio
Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2006;8(11):826-9.
2006: Miguel Martín; Ana Lluch; Miguel Angel Seguí; Amparo Ruiz; M Ramos; Encarna Adrover; Alvaro Rodríguez-Lescure; R Grosse; Lourdes Calvo; C Fernandez-Chacón; M Roset; Antonio Antón; Dolores Isla; P Martínez del Prado; L Iglesias; J Zaluski; Angels Arcusa; José Manuel López-Vega; Monserrat Muñoz; J R Mel
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(8):1205-12.
2006: Miguel Martín
Molecular biology of breast cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2006;8(1):7-14.
2005: Jose M Jerez; Leonardo Franco; Emilio Alba; Antonio Llombart-Cussac; Ana Lluch; Nuria Ribelles; Blanca Munárriz; Miguel Martín
Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks.
Breast cancer research and treatment 2005;94(3):265-72.
2005: José A García-Sáenz; Miguel Martín; Javier Puente; Sara López-Tarruella; Antonio Casado; Fernando Moreno; Enrique Grande; Eduardo Díaz-Rubio
Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.
Clinical breast cancer 2005;6(4):325-9.
2004: Emilio Alba; Miguel Martín; Manuel Ramos; Encarna Adrover; Anna Balil; Carlos Jara; Agustí Barnadas; Antonio Fernández-Aramburo; Pedro Sánchez-Rovira; Margarita Amenedo; Antonio Casado
Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(13):2587-93.
2004: ramon colomer; G Viñas; M Beltran; Angel Izquierdo; Ana Lluch; Antonio Llombart-Cussac; Emilio Alba; Blanca Munárriz; Miguel Martín
Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):961-2.
2004: Miguel Martín; Antonio Llombart-Cussac; Ana Lluch; Emilio Alba; Blanca Munárriz; Ignasi Tusquets; Agustí Barnadas; Anna Balil; Javier Dorta; César Picó
[Epidemiological study of the GEICAM group about breast cancer in Spain (1990-1993): El Alamo project].
Medicina clínica 2004;122(1):12-7.
2003: Carlos Jara-Sánchez; Miguel Martín; José A García-Sáenz; Agustí Barnada; Antonio Fernández-Aramburo; José Manuel López-Vega; Amadeu Pelegrí; Emilio Alba; Antonio Casado
Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group.
Clinical breast cancer 2003;3(6):399-404.
2002: José A García-Sáenz; Miguel Martín; Antonio Casado; Pedro Pérez-Segura; Isabel Manrique; L Flores; J A Macias; J C Cámara; C Perezagua; Eduardo Díaz-Rubio
Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: results of a randomized study.
Revista española de quimioterapia : publicación oficial de la Sociedad Española de Quimioterapia 2002;15(3):257-63.
2001: Miguel Martín
Platinum compounds in the treatment of advanced breast cancer.
Clinical breast cancer 2001;2(3):190-208; discussion 209.
2000: Miguel Martín; Antonio Casado; J A Macias; Iciar Garcia Carbonero; J A Garcia-Saenz; M Oruezabal; Isabel Manrique; Eduardo Diaz-Rubio
Methotrexate, uracil and tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemotherapy with peripheral blood progenitor cell transplant: a phase II study.
American journal of clinical oncology 2000;23(6):617-21.
1998: Yago Nieto; J L Alonso; F Ayala; L Ortega; A Casado; Miguel Martín; E Díaz-Rubio
End-stage acute hepatic failure as clinical presentation of liver metastases from breast cancer.
Tumori 1998;84(5):616-7.
1998: Yago Nieto; Miguel Martín; J L Alonso; A Casado; F Ayala; Jose A Lopez-Martin; A Rodríguez-Lescure; Eduardo Díaz-Rubio
Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin.
Breast cancer research and treatment 1998;50(2):167-74.
1997: Miguel Martín; A Casado; L Llorente; Jose A Lopez-Martin; A Rodríguez Lescure; Yago Nieto; F Ayala; J Pérez Calvo; J L Alonso; C Pérez López; A Villegas; Eduardo Díaz-Rubio
[High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer].
Medicina clínica 1997;109(20):775-81.
1996: A Fernández-Marcos; Miguel Martín; Jose A Lopez-Martin; A Rodriguez-Lescure; Antonio Casado; J A López Martin; Eduardo Diaz-Rubio
Acute and anticipatory emesis in breast cancer patients.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1996;4(5):370-7.
1996: Jose A Lopez-Martin; Yago Nieto; J A López; Miguel Martín; Eduardo Díaz-Rubio
Ifosfamide encephalopathy and methylene-blue: a case report.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(6):643-4.
1996: Antonio Casado; Rafael Rosell; R García-Gómez; Eduardo Díaz-Rubio; G Pérez-Manga; Albert Font; A Benavides; Miguel Martín
Phase II study of mitonafide in non-small cell lung cancer (NSCLC).
Investigational new drugs 1996;14(4):415-7.
1996: Albert Abad; C Grávalos; Albert Font; F Molina; M T Díaz-Puente; Xavier Fabregat; A Benavides; Miguel Martín
Phase II study of Mitonafide in advanced and relapsed colorectal cancer.
Investigational new drugs 1996;14(2):223-5.
1994: Miguel Martín; Ana Lluch; Antonio Casado; P Santabárbara; E Adrover; J J Valverde; Jose A Lopez-Martin; A Rodriguez-Lescure; P Azagra; Javier García Conde
Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(5):986-91.
1994: Eduardo Díaz-Rubio; Miguel Martín; J M López-Vega; Antonio Casado; A Benavides
Phase I study of mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity.
Investigational new drugs 1994;12(4):277-81.
1993: Miguel Martín; Eduardo Diaz-Rubio; José Luis González-Larriba; Antonio Casado; Javier Sastre; J M López-Vega; JOSE ALMENAREZ; S Dominguez
Ifosfamide in advanced epidermoid head and neck cancer.
Cancer chemotherapy and pharmacology 1993;31(4):340-2.
1992: Miguel Martín; Eduardo Díaz-Rubio; Antonio Casado; P Santabárbara; J M López Vega; E Adrover; L Lenaz
Carboplatin: an active drug in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):433-7.
1991: M P Morales; Miguel Martín; Eduardo Díaz-Rubio; José Luis González-Larriba; L Audibert; Antonio Casado; JOSE ALMENAREZ
[Superior vena cava syndrome in microcytic carcinoma of the lung: incidence, treatment response and prognostic importance].
Revista clínica española 1991;189(6):268-71.
1991: Miguel Martín; Eduardo Díaz-Rubio
[Control of colorectal cancer recurrence treated with curative surgery: results of a prospective study].
Revista clínica española 1991;188(7):339-44.
1990: Eduardo Díaz-Rubio; José Luis González-Larriba; Rafael Rosell; A Abad; Miguel Martín; J J Valerdi; J J Barriga
Randomized, double-blind cross-over study of acute cisplatin-induced nausea and vomiting, comparing a new schedule of the combination of metoclopramide and methylprednisolone versus metoclopramide alone.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(5):379-80.